The DSIP-CBBBP group, in particular, showed superior improvement over both the model and DSIP-only groups, suggesting enhanced efficacy of the fusion peptide
Cancer There are many publications dealing with the peptide as an effective cytoprotective agent
AOD-9604 10mg is the preferred format for established research programmes with higher throughput requirements, dose-response studies, multi-arm experiments comparing several concentration levels, or extended research programmes requiring multiple experimental runs
As of April 2026, the following clinical realities must be noted: Limited Human Trials: While Phase 1/2 exploratory studies have investigated peptide safety and local administration (e.g., intra-articular for osteoarthritis), large-scale Randomized Controlled Trials (RCTs) confirming systemic efficacy in humans are absent (Dove Medical Press, 2025)
This ensures every vial you receive meets rigorous quality standardsverified not just by us, but by trusted independent labsso you can conduct your research with total confidence